Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Alvotech

Market Cap 1.3B 1.12B 1.04B 970M 1.82B 124B 1.85B 12.23B 4.77B 60.22B 4.89B 4.78B 209B P/E Ratio 2026 *
10.4x
P/E Ratio 2027 * 9.55x
Enterprise Value 2.4B 2.07B 1.91B 1.79B 3.35B 228B 3.4B 22.56B 8.8B 111B 9.01B 8.82B 385B EV / Sales 2026 *
3.63x
EV / Sales 2027 * 3.09x
Free-Float
36.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week+17.80%
Current month+24.11%
1 month+17.46%
3 months+17.80%
6 months-25.13%
Current year-18.71%
1 week 3.62
Extreme 3.62
4.59
1 month 2.94
Extreme 2.94
4.59
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.94
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
04-01Free

Chief Executive Officer

117,271 0.0355%
04-01Buy

Founder

318,000 0.0963%
04-01Sell

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%+17.80%-57.62%-43.80% 1.3B
-0.35%+0.97%-15.96%-12.73% 43.03B
+3.11%+3.11%+274.29%+507.94% 32.71B
+0.22%-1.08%+14.03%-14.37% 30.29B
+1.62%-2.08%-4.36%+24.05% 29.4B
+4.09%+0.93%+10.83%+18.78% 25.08B
-1.63%+2.88%+53.73%+114.36% 13.35B
+1.14%+3.62% - - 13.54B
-0.40%-1.29%+6.06%+7.59% 12.97B
-0.74%-1.62%+105.71%+76.01% 12.11B
Average +0.59%+1.14%+42.97%+75.32% 21.38B
Weighted average by Cap. +1.04%+1.46%+54.21%+96.39%

Financials

2026 *2027 *
Net sales 661M 571M 526M 492M 923M 62.8B 937M 6.21B 2.42B 30.57B 2.48B 2.43B 106B 784M 677M 624M 584M 1.09B 74.51B 1.11B 7.37B 2.87B 36.27B 2.94B 2.88B 126B
Net income 165M 142M 131M 123M 230M 15.68B 234M 1.55B 604M 7.63B 619M 606M 26.42B 134M 116M 107M 99.87M 187M 12.74B 190M 1.26B 491M 6.2B 503M 492M 21.47B
Net Debt 1.1B 949M 875M 819M 1.53B 104B 1.56B 10.33B 4.03B 50.84B 4.12B 4.04B 176B 1.12B 967M 891M 834M 1.56B 106B 1.59B 10.52B 4.1B 51.79B 4.2B 4.11B 179B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
12/06/26 4.170 $ -1.18% 533,765
11/06/26 4.220 $ +1.93% 896,655
10/06/26 4.140 $ -0.48% 617,621
09/06/26 4.160 $ -1.89% 1,431,206
08/06/26 4.240 $ +19.77% 2,265,909
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
4.170USD
Average target price
13.83USD
Spread / Average Target
+231.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!